# MIMARK Diagnostics S.L.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mimark-diagnostics-s-l

- Industry: Medical Devices & Equipment
- Headquarters: Barcelona, Spain
- Website: www.mimark.es
- Total disclosed funding: $4.6M
- Latest round: Seed (Nov 27, 2023)
- Investors on record: 7

## About

Founed in 2021 and based in Barcelona, Spain by CEO Marina Rigau, CSO Eva Colás, and CMO Antonio Gil, MIMARK Diagnostics S.L, a.k.a. MIMARK Diagnostics is developing in vitro diagnostic solutions to improve the management of gynecological malignancies, as well as enhance endometrial cancer diagnosis. In June 2023, MIMARK Diagnostics S.L raised EUR 1 million in venture funding co-led by Clave Capital, Nara Capital, and Namarel Ventures, with participation from Women Angels for STEAM.

The company provides WomEC, which is an in vitro diagnostic test for endometrial cancer based on the analysis of proteins in the soluble fraction of a uterine aspirate sample. WomEC offers patients a diagnosis of endometrial cancer, which is less invasive and accurate, enabling the improvement in the management of patients with suspected cancer.

MIMARK Diagnostics plans to use its proceeds from June 2023 funding to accelerate the development of in vitro diagnostic tests for cancer.

## Funding rounds

- Seed, Nov 27, 2023, $4.6M — Inveready Asset Management, Clave Capital, Women Angels for STEAM, Canterbury Scientific Ltd, Nara Capital, Namarel Ventures, CDTI Innovation

## Investors

- Inveready Asset Management (https://capitalatlas.ai/funds/inveready-asset-management) — Seed
- Clave Capital — Seed
- Women Angels for STEAM — Seed
- Canterbury Scientific Ltd — Seed
- Nara Capital (https://capitalatlas.ai/funds/nara-capital) — Seed
- Namarel Ventures (https://capitalatlas.ai/funds/namarel-ventures) — Seed
- CDTI Innovation — Seed